Contineum Therapeutics, Inc. Class A Common Stock Asset Resilience Ratio
Contineum Therapeutics, Inc. Class A Common Stock asset resilience ratio. Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has an Asset Resilience Ratio of 88.61% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Contineum Therapeutics, Inc. Class A Com to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
Asset resilience ratio of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025. This chart shows how Contineum Therapeutics, Inc. Class A Common Stock's Asset Resilience Ratio has changed over time. Read Contineum Therapeutics, Inc. Class A Com debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Contineum Therapeutics, Inc. Class A Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CTNM total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $221.84 Million | 88.61% |
| Total Liquid Assets | $221.84 Million | 88.61% |
Asset Resilience Insights
- Very High Liquidity: Contineum Therapeutics, Inc. Class A Common Stock maintains exceptional liquid asset reserves at 88.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Contineum Therapeutics, Inc. Class A Common Stock Industry Peers by Asset Resilience Ratio
Compare Contineum Therapeutics, Inc. Class A Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Contineum Therapeutics, Inc. Class A Common Stock Asset Resilience Ratio by Year (2021–2025)
Contineum Therapeutics, Inc. Class A Common Stock asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Contineum Therapeutics, Inc. Class A Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 67.70% | $187.29 Million | $276.64 Million | -18.19pp |
| 2024-12-31 | 85.89% | $182.82 Million | $212.85 Million | +1.78pp |
| 2023-12-31 | 84.11% | $109.66 Million | $130.39 Million | +1.81pp |
| 2022-12-31 | 82.29% | $41.67 Million | $50.64 Million | -8.99pp |
| 2021-12-31 | 91.29% | $64.37 Million | $70.52 Million | -- |
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibr… Read more